Glycemic Control and Cardiovascular Disease: What’s a Doctor to Do?
- 1 April 2012
- journal article
- research article
- Published by Springer Nature in Current Diabetes Reports
- Vol. 12 (3) , 255-264
Abstract
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in individuals with diabetes mellitus. Moreover, rates of CVD mortality are two to four times higher in diabetes than in those without diabetes. It was conventional thinking that achieving near-normoglycemia would help reduce CVD risk and overall mortality in type 2 diabetes mellitus. Several recent large trials attempted to answer this question using a randomized control trial design with a conventional therapy and an intensive control arm. Surprisingly, these trials did not demonstrate neither mortality nor a CVD advantage with intensive glycemic control. Moreover, some studies (e.g., the ACCORD [Action to Control Cardiovascular Risk in Diabetes] study) showed increased mortality in the intensive control arm. In this review, our goal is to summarize the findings of the major trials in this field and to explore the potential reasons for why these trials had largely negative results. We conclude with some lessons that may be applied to the clinical management of patients with diabetes.Keywords
This publication has 75 references indexed in Scilit:
- Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to ComorbiditiesThe American Journal of Medicine, 2011
- Glycated Hemoglobin, Diabetes, and Cardiovascular Risk in Nondiabetic AdultsNew England Journal of Medicine, 2010
- 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes StudyThe Lancet, 2009
- A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery DiseaseNew England Journal of Medicine, 2009
- Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients With Type 1 Diabetes MellitusArchives of Ophthalmology (1950), 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesNew England Journal of Medicine, 2008
- Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysisThe Lancet, 2008